Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.91
78.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Total Other Income
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
|
Total Other Income
-ÂĄ18.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Other Income
-ÂĄ654k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Other Income
-ÂĄ25.8m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-79%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Glance View
Sunshine Guojian Pharmaceutical Shanghai Co., Ltd. stands as a beacon of innovation in China’s bustling pharmaceutical landscape. Born from a vision to advance biotech research and development, the company has centered its efforts on the creation of monoclonal antibody drugs. These biologics are pivotal in treating complex diseases such as cancers and autoimmune disorders, positioning Sunshine Guojian at the forefront of biopharmaceutical excellence. The company's prowess is anchored in its robust R&D capabilities, with a specialized team of scientists and cutting-edge facilities driving the creation of therapeutics that meet global standards. By strategically focusing on biologics, the firm not only taps into a growing demand for advanced medical solutions but also strengthens its competitive edge in both domestic and international markets. The economic engine of Sunshine Guojian hums along with a well-oiled strategy of clinical development and commercialization. Partnering with healthcare professionals and institutions, the company ensures that its biologics are effectively integrated into treatment paradigms, thereby enhancing patient care and outcomes. Revenue streams flow through a mix of direct sales and strategic partnerships, both within China and abroad, where collaborative alliances help broaden market reach and drive scale. Moreover, its established networks enable the company to stay attuned to emerging medical needs and regulatory environments, adapting swiftly to maintain its leadership position. This adeptness in maneuvering the complex web of pharmaceutical offerings allows Sunshine Guojian not just to survive but to thrive, fueling sustainable growth and innovation in an ever-evolving health landscape.
See Also
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Total Other Income?
Total Other Income
-18.9m
CNY
Based on the financial report for Dec 31, 2024, Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Total Other Income amounts to -18.9m CNY.
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Total Other Income growth rate?
Total Other Income CAGR 5Y
9%
Over the last year, the Total Other Income growth was -149%. The average annual Total Other Income growth rates for Sunshine Guojian Pharmaceutical Shanghai Co Ltd have been -24% over the past three years , 9% over the past five years .